Who are Copaxone-Teva's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BG00012 (DMF), Interferon-Alpha, CMP 001, Ixazomib plus low-dose lenalidomide, Drug: Carfilzomib + Lenalidomide + Dexamethasone, histamine dihydrochloride and IL-2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/copaxone-teva.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Copaxone-Teva — Competitive Intelligence Brief

Copaxone-Teva (Copaxone-Teva) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator; synthetic polypeptide. Area: Neurology; Immunology.

phase 3 Immunomodulator; synthetic polypeptide T cell receptor (indirect); myelin basic protein mimic Neurology; Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Copaxone-Teva (Copaxone-Teva) — Biocad. Glatiramer acetate is a synthetic polypeptide that modulates immune responses by promoting anti-inflammatory T cell and B cell activity in multiple sclerosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Copaxone-Teva TARGET	Copaxone-Teva	Biocad	phase 3	Immunomodulator; synthetic polypeptide	T cell receptor (indirect); myelin basic protein mimic
BG00012 (DMF)	BG00012 (DMF)	Biogen	marketed	Fumaric acid ester; immunomodulator	Nrf2 (nuclear factor erythroid 2-related factor 2)
Interferon-Alpha	Interferon-Alpha	University of Birmingham	marketed	Cytokine; Immunomodulator	Interferon-alpha receptor (IFNAR)
CMP 001	cmp-001	Pfizer Inc.	marketed	Immunomodulatory Agent	TLR9
Ixazomib plus low-dose lenalidomide	Ixazomib plus low-dose lenalidomide	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Proteasome inhibitor and immunomodulatory agent	Proteasome and cereblon
Drug: Carfilzomib + Lenalidomide + Dexamethasone	Drug: Carfilzomib + Lenalidomide + Dexamethasone	Amgen	marketed	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
histamine dihydrochloride and IL-2	histamine dihydrochloride and IL-2	Cytovia, Inc.	marketed	Immunomodulator combination	Histamine receptors (H1, H2, H3, H4) and IL-2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator; synthetic polypeptide class)

Biocad · 1 drug in this class
Synthon BV · 1 drug in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Copaxone-Teva — Competitive Intelligence Brief. https://druglandscape.com/ci/copaxone-teva. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab